Announcement on Changes in the Company's Accounting Policy
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2019-018
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Changes in Accounting Policies of the Company
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
● This change in accounting policy will not have a significant impact on the company's financial position and operating results.
Overview of 1. Accounting Policy Change
1 , 2018 6 15 , the Ministry of Finance issued the Notice on the Revision and Issuance of the Format of Financial Statements of General Enterprises for the Year 2018 (Caihui [2018] No. 15 ), which requires non-financial enterprises implementing corporate accounting standards to prepare their financial statements in accordance with the revised format of financial statements of general enterprises.
2 , the Ministry of Finance successively revised and issued "Accounting Standards for Business Enterprises No. 22 -Recognition and Measurement of Financial Instruments", "Accounting Standards for Business Enterprises No. 23 -Transfer of Financial Assets", "Accounting Standards for Business Enterprises No. 24 -Hhedge Accounting" and "Accounting Standards for Business Enterprises No. Accounting standards related to four financial instruments, including 37 -Presentation of Financial Instruments, enterprises listed at home and abroad at the same time since 2018 , , 1 , , , and enterprises listed abroad and adopting international financial reporting standards or enterprise accounting standards to prepare financial reports will be implemented in other domestic listed enterprises since 2019 , , 1 , , .
2019 1 May 1 .
The Company implemented the relevant rules in accordance with the "Notice on Revising and Issuing the Format of General Enterprise Financial Statements for 2018
[2018] No. 15 ) revised and issued by 2018 # above accounting policies. Other unchanged parts are still implemented in accordance with the "Accounting Standards for Enterprises-Basic Standards" and related specific standards issued by the Ministry of Finance in the previous period, the application guide of accounting standards for enterprises, the interpretation of accounting standards for enterprises and other relevant regulations. Revision of the Guidelines for (II) Financial Instruments
. Amend the accounting treatment of impairment of financial assets from "incurred loss method" to "expected loss method", it is required to consider the expected credit loss of financial assets in the future, so as to make provision for impairment of financial assets in a more timely and full manner;
, adjust the accounting treatment of non-trading equity instrument investment, allow enterprises to designate non-trading equity instrument investment as measured at fair value and its changes are included in other comprehensive income for treatment, but the designation is irrevocable, and at the time of disposal, the accumulated fair value changes originally included in other comprehensive income shall not be carried forward and included in the current profit and loss;
, further clarify the judgment principle of financial asset transfer and its accounting treatment;
, hedge accounting standards put more emphasis on the organic combination of hedge accounting and enterprise risk management activities, better reflect the risk management activities of the enterprise.
2019 July . According to the relevant requirements of the convergence provisions in the new financial instruments standard, the company will not make retroactive adjustments to the comparative statements for the same period of the previous year, and this change in accounting policy will not affect the relevant financial indicators of the company 2018 .
This change in accounting policy will not have a significant impact on the company's financial position and operating results.
4. Board Review
2019 April 17 March 26 , the company held the 10th 176 meeting. After review and voting, 9 votes in favor, 0 votes against, 0 votes abstained, the bill on the change of the company's accounting policy was considered and passed.
l
Founding Document
Resolution of the 214 Meeting of the 9th Board of Supervisors of the (II)
Independent Opinions of (III) Independent Directors
This is to announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 30, 2009
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page